A Study to Investigate the Efficacy and Safety of Volrustomig Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC

• Status: RECRUITING
• Trial end date: 2032-07-29

Summary

This is a Phase Ib/III, randomized, multicenter, global study evaluating the efficacy and safety of volrustomig in combination with casdatifan for the first-line (1L) treatment of participants with advanced clear cell renal cell carcinoma (ccRCC).

• Phase: PHASE3

Details

• Lead Sponsor: AstraZeneca
• Collaborator: Arcus Biosciences, Inc.
• Treatments: Ipilimumab; Nivolumab